SCHLAGWORTE: Life Sciences
Microcirculation is key
The mission of the Swiss biopharmaceutical Topadur is not only to dilate blood vessels, but also to cause them to regenerate. Its innovative drugs,...
The ultimate funding hack? A real value proposition and strong industry...
Public funding mitigates risks, but it cannot replace equity. Life sciences founders who merely jump from one funding deadline to the next, or who...
Capital for scientists: navigating the German funding maze strategically
Drug development, medical technology, or digital health: few industries are as capital-intensive as the life sciences. Yet, knowing precisely when to submit which application...
Swiss Biotech Day 2026 in Basel
The Swiss Biotech Day 2026 has kicked off in Basel from May 4-5, once again positioning Switzerland at the center of the global biotech...
Swiss biotech report: Robust performance in 2025
Switzerland’s biotech sector delivered a robust performance in 2025, underlining its resilience in a challenging global environment. According to the Swiss Biotech Report 2026,...
mbiomics erhält weitere 12 Mio. EUR
Das Start-up mbiomics, das skalierbare, mikrobiombasierte Therapeutika für schwere und chronische Erkrankungen entwickelt, hat im dritten Abschluss seiner Serie-A-Finanzierungsrunde weitere 12 Mio. EUR eingesammelt. ...
Brussels‘ biotech offensive: an overdue signal with flaws
Together with leading chinical research and legal experts, we analyse: is Brussels' 75-day fast-track enough to stop the innovation drain, or does the lack...
Onyx Biotech erhält Kapital für High-Tech Medikamentenentwicklung
Onyx Biotech erhält Pre-Seed-Kapital von Life Science Valley Wachstumsfonds, Freiraum Ventures und Business Angels für seine moderne Medikamentenentwicklung.
Onyx Biotech entwickelt best-in-class Algorithmen und Workflows,...
Financing research – even retrospectively
When the pandemic broke out in 2020, medical research around the world was under intense pressure. Everything had to happen at once: the so-called...
‚Life sciences are the ultimate impact investment‘
Robin Lauber is a third-generation heir, serial entrepreneur, and investor. Since 2015, he has developed the single-family office Infinitas Capital into a vertically integrated...
Gilead Sciences to acquire Tubulis for up to $5 billion
US biopharmaceutical giant Gilead Sciences is acquiring the biotech start-up Tubulis, significantly expanding its oncology division. The transaction includes an upfront cash payment of...
Out now: Impact Life Sciences 01/26!
Like a sword of Damocles, a concern hangs over every life sciences start-up founded in Germany: will the company remain headquartered in Germany –...
Secarna Pharmaceuticals: Jens Holstein und Richard Mark Engelhard zu Beiratsmitgliedern ernannt
Secarna Pharmaceuticals GmbH & Co. KG, ein Unternehmen, das die Erforschung und Entwicklung von Oligonukleotid-Therapeutika neu definiert, gab heute die Einrichtung eines Beirats bekannt,...
Life Science Pitch Day 2026
HTGF und das Innovations- und Gründerzentrum für Biotechnologie (IZB) veranstalten am 2. Juli in München den 10. jährlichen Life Science Pitch Day. Der diesjährige...
From Lab to Launch: So gelingt Life Sciences-Start-ups die Series A
Life Sciences gehören zu den spannendsten, aber auch anspruchsvollsten Bereichen für Wachstumskapital. Kaum ein Sektor verbindet wissenschaftliche Exzellenz so direkt mit gesellschaftlichem Nutzen und...